4 December 2024
N4 Pharma
plc
("N4 Pharma" or the
"Company")
New Patent
Filing
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing novel RNA therapeutics
usings its proprietary delivery systems, is pleased to announce it
has filed a new patent for its oral anti-inflammatory
Irritable Bowel Disease ("IBD") product in early pre-clinical development.
The orally delivered product uses
the unique capabilities of the Company's Nuvec® delivery system to
target the macrophage cells responsible for the inflammation
associated with IBD. Each Nuvec® nanoparticle contains two separate
RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to
promote the body's natural anti-inflammatory defenses. By
delivering these RNA together locally in the gut, the symptoms of
IBD can be more readily treated.
The patent has been filed with the
UK patent office.
Please visit the N4 Pharma Investor
Hub to submit any questions and find more information, including an
additional video by Nigel Theobald, CEO: https://investors.n4pharma.com/link/XyO8oe.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"We are excited by the potential of this product as it not
only addresses a strong clinical need to replace injectable
TNF-alpha inhibitors and other oral solutions with significant side
effects, it also showcases the key features of the Nuvec® system,
namely the ability to protect the payload, target delivery to a
particular cell type and load multiple RNA onto the one
nanoparticle.
"By filing the patent, we are now able to talk in more detail
to our investors and potential collaborators about this product and
will shortly provide an update on the in-vitro work we have
completed giving more detail regarding our
approach."
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
Investor questions on this announcement
We encourage all investors to share
questions
on this announcement via our investor
hub
|
Via N4 Pharma Investor Hub
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/XyO8oe
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe
(Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob
Rees (Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
|
Tel: +44(0)20 3657 0050
|
|
|
|
Glossary
RNA: Ribonucleic acid, present in all
living cells
mRNA: messenger RNA, whose role is to
carry protein information from the DNA in a cell's nucleus to the
cells cytoplasm to produce a particular protein.
siRNA: small interfering RNA, a short
double-stranded RNA, one of whose strands can complement and
inactivate a sequence mRNA to stop protein production.
About N4 Pharma
N4 Pharma is a pre-clinical biotech
company developing unique nucleic acid based products using its
patented delivery systems Nuvec® and Liptide®. Its first two
products are an oral anti-inflammatory product for IBD and an siRNA
to knock down MRTF-B which reduces scarring post Glaucoma surgery.
As well as these it is looking to develop further oncology and gene
therapy products.
Its novel delivery systems are also
available to third parties for licensing to develop their own
products in oncology, gene therapy and vaccines for upfront
payments, milestone payments and ultimately royalty payments once
products reach the market.
It is also seeking partners or
investors to take its initial products into phase 1 clinical
trials.
For further information on the
Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.